Back to User profile » Dr Filippo de Marinis

Papers published by Dr Filippo de Marinis:

Original Research

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JCH, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SHI

Lung Cancer: Targets and Therapy 2019, 10:125-130

Published Date: 13 November 2019

Review

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

Passaro A, Lazzari C, Karachaliou N, Spitaleri G, Pochesci A, Catania C, Rosell R, de Marinis F

OncoTargets and Therapy 2016, 9:6361-6376

Published Date: 17 October 2016

Case report

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

Spitaleri G, Biffi R, Barberis M, Fumagalli C, Toffalorio F, Catania C, Noberasco C, Lazzari C, de Marinis F, De Pas T

OncoTargets and Therapy 2015, 8:1997-2003

Published Date: 18 August 2015

Case report

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

Catania C, Conforti F, Spitaleri G, Barberis M, Preda L, Noberasco C, Lazzari C, Toffalorio F, de Marinis F, Manzotti M, De Pas TM

OncoTargets and Therapy 2014, 7:697-702

Published Date: 8 May 2014